4 / 5 Stars
5 3 1 5 5
Zacks Investment Research
1 (Strong Buy)
Standard & Poor's
5 / 5 Stars
#4 in Health
U.S. News evaluated 38 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
The fund has returned 103.48 percent over the past year, 49.65 percent over the past three years, 23.52 percent over the past five years, and 15.67 percent over the past decade.
|Trailing Returns||Updated 05.31.2013|
|Year to date||57.7%|
|3 Years (Annualized)||49.7%|
|5 Years (Annualized)||23.5%|
|10 Years (Annualized)||15.7%|
The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund invests in securities and derivatives that the adviser believes, in combination, should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified.
Fees are Average compared to funds in the same category.
ProFunds Biotechnology UltraSector Fund has an expense ratio of 1.73 percent.
Risk is High compared to funds in the same category according to Morningstar.